Regulation of Drug Manufacturing: An Introduction
Examine Current Good Manufacturing Practices (cGMPs) for drugs and define “adulteration” and “misbranding”. Review the different types of inspections, including the differences between foreign and domestic inspections. Explore the elements of a 483 observation and the components involved in closing out an inspection.
Cathy L. Burgess, Partner, Alston & Bird LLP
This session was recorded as part of FDLI’s Virtual Introduction to Drug Law and Regulation Course in April 2020.
- +$100 for nonmembers
Virtual Learning FAQ
On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.
On-demand content can be played back on most devices.
If you have concerns, please click the Test Your System link to determine your device’s compatibility, as well as system requirements.
CLE credit is not currently available for pre-recorded sessions.